Market News & Analysis


Top Story

FTSE fares better than peers as UK gets ready to reopen

The Prime Minister is due to lay out plans to reopen UK work places at some point this week and documents leaked to the Sunday newspapers provided a glimpse into the blue print.  Staggered shifts, social distancing and plastic screens in shops and bank branches will be put in place so that businesses and retail outlets can open their doors again. Unlike its European peers the FTSE started the week on a slightly positive note, initially withstanding the tide of negative sentiment prompted by renewed tariff fears after President Trump intesified his attacks on China.

In London, Ppharma firms, waste disposal firm Rentokill Initial and delivery group Ocado are among the top gainers this morning, followed by gold miner Polymetal, a corona defence stock. Hikma Pharmaceuticals, a maker of non-branded generic medication, continued last week’s rally which was prompted by the company reporting revenue growth despite difficult market conditions. 

This week could see several heated boardroom discussions over chief executives’ bonus payments starting with Ocado where chief executive Tim Steiner expects to see a payout of £59m in the form of a long term bonus. GlaxoSmithKline and Barclays will also have board meetings this week.

BoE’s quarterly inflation report

This week’s Bank of England quarterly inflation report is bound to make uncomfortable reading, showing for the first time in detail how big an impact the last month and a half of the lockdown have had on the UK economy. The big question is, will the Bank be able to continue with the emergency bond purchases announced in March or will it start having to reduce its quantitative easing programme?

From time to time, GAIN Capital Australia Pty Ltd (“we”, “our”) website may contain links to other sites and/or resources provided by third parties. These links and/or resources are provided for your information only and we have no control over the contents of those materials, and in no way endorse their content. Any analysis, opinion, commentary or research-based material on our website is for information and educational purposes only and is not, in any circumstances, intended to be an offer, recommendation or solicitation to buy or sell. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. No representation or warranty is made, express or implied, that the materials on our website are complete or accurate. We are not under any obligation to update any such material.

As such, we (and/or our associated companies) will not be responsible or liable for any loss or damage incurred by you or any third party arising out of, or in connection with, any use of the information on our website (other than with regards to any duty or liability that we are unable to limit or exclude by law or under the applicable regulatory system) and any such liability is hereby expressly disclaimed.